| Primary |
| Product Used For Unknown Indication |
36.3% |
| Blood Testosterone Decreased |
22.7% |
| Hypertension |
7.2% |
| Hypogonadism |
5.2% |
| Drug Use For Unknown Indication |
4.9% |
| Ill-defined Disorder |
3.9% |
| Blood Cholesterol Increased |
2.8% |
| Androgen Deficiency |
2.6% |
| Pain |
2.1% |
| Accidental Exposure |
2.0% |
| Diabetes Mellitus |
2.0% |
| Muscle Building Therapy |
1.2% |
| Anxiety |
1.1% |
| Coronary Artery Disease |
0.9% |
| Depression |
0.9% |
| Hypothyroidism |
0.9% |
| Prophylaxis |
0.9% |
| Cardiac Disorder |
0.8% |
| Arthritis |
0.7% |
| Erectile Dysfunction |
0.7% |
|
| Drug Ineffective |
18.5% |
| Rash |
11.2% |
| Pulmonary Embolism |
7.9% |
| Blood Testosterone Increased |
7.3% |
| Accidental Exposure |
5.1% |
| Blood Testosterone Decreased |
4.5% |
| Drug Administered At Inappropriate Site |
4.5% |
| Product Quality Issue |
4.5% |
| Myocardial Infarction |
3.9% |
| Blood Testosterone Abnormal |
3.4% |
| Prostatic Specific Antigen Increased |
3.4% |
| Therapeutic Response Decreased |
3.4% |
| Weight Increased |
3.4% |
| Aggression |
2.8% |
| Alopecia |
2.8% |
| Application Site Rash |
2.8% |
| Dizziness |
2.8% |
| Oedema Peripheral |
2.8% |
| Precocious Puberty |
2.8% |
| Anxiety |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
23.0% |
| Blood Testosterone Decreased |
19.2% |
| Hormone Replacement Therapy |
9.5% |
| Hypertension |
8.4% |
| Drug Use For Unknown Indication |
6.6% |
| Depression |
4.1% |
| Pain |
3.2% |
| Headache |
3.1% |
| Hypogonadism |
3.1% |
| Blood Pressure |
2.8% |
| Blood Cholesterol Increased |
2.7% |
| Diabetes Mellitus |
2.7% |
| Menopause |
2.2% |
| Ear Pain |
1.7% |
| Sleep Disorder |
1.7% |
| Menopausal Symptoms |
1.5% |
| Anxiety |
1.1% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Hypopituitarism |
1.1% |
| Prophylaxis |
1.1% |
|
| Drug Ineffective |
18.2% |
| Blood Testosterone Decreased |
9.1% |
| Breast Cancer |
8.3% |
| Blood Testosterone Abnormal |
6.1% |
| Breast Cancer Metastatic |
5.3% |
| Tremor |
5.3% |
| Supraventricular Tachycardia |
4.5% |
| Blood Testosterone Increased |
3.8% |
| Breast Cancer Female |
3.8% |
| Prostate Cancer |
3.8% |
| Rash |
3.8% |
| Weight Increased |
3.8% |
| Erythema |
3.0% |
| Fatigue |
3.0% |
| Headache |
3.0% |
| Malaise |
3.0% |
| Pain |
3.0% |
| Product Quality Issue |
3.0% |
| Prostatic Specific Antigen Increased |
3.0% |
| Pulmonary Embolism |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
23.7% |
| Drug Use For Unknown Indication |
9.5% |
| Hiv Infection |
7.6% |
| Hypertension |
5.8% |
| Blood Follicle Stimulating Hormone Decreased |
4.6% |
| Blood Luteinising Hormone Decreased |
4.5% |
| Hypopituitarism |
4.5% |
| Depression |
3.9% |
| Primary Hypothyroidism |
3.9% |
| Hypogonadism Male |
3.6% |
| Blood Corticotrophin Decreased |
3.6% |
| Growth Hormone Deficiency |
3.5% |
| Pain |
3.4% |
| Blood Thyroid Stimulating Hormone Decreased |
3.2% |
| Follicle-stimulating Hormone Deficiency |
3.1% |
| Essential Hypertension |
2.5% |
| Testicular Hypogonadism |
2.4% |
| Hypothyroidism |
2.3% |
| Osteoporosis |
2.3% |
| Diabetes Mellitus |
2.3% |
|
| Weight Decreased |
13.2% |
| Weight Increased |
7.9% |
| Drug Ineffective |
7.2% |
| Vomiting |
7.0% |
| Death |
6.9% |
| Pneumonia |
6.4% |
| Pain |
5.3% |
| Pituitary Tumour Benign |
5.0% |
| Arthropathy |
4.3% |
| Vision Blurred |
4.0% |
| Flushing |
3.9% |
| Pruritus |
3.7% |
| Pulmonary Embolism |
3.7% |
| Cerebrovascular Accident |
3.6% |
| Pain In Extremity |
3.4% |
| Sleep Disorder |
3.0% |
| Tremor |
3.0% |
| Cardiac Disorder |
2.9% |
| Nausea |
2.9% |
| Pyrexia |
2.7% |
|
| Interacting |
| Blood Testosterone Decreased |
25.0% |
| Drug Use For Unknown Indication |
16.7% |
| Hypertension |
16.7% |
| Blood Pressure Abnormal |
8.3% |
| Erectile Dysfunction |
8.3% |
| Growth Hormone Deficiency |
8.3% |
| Hypogonadism |
8.3% |
| Rash |
8.3% |
|
| Drug Ineffective |
40.0% |
| Drug Interaction |
20.0% |
| Treatment Noncompliance |
20.0% |
| Tremor |
20.0% |
|
